Jun, 2019 Others
Global Dengue Vaccine Market Insights, Forecast to 2025
Category by- Others , No. of Pages - 110, Published By - Global QYResearch
The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking.
With the increasing population density and global warming, there is a rapid growth in the prevalence of dengue, especially in the tropical and subtropical regions across the world. According to the National Institute of Health, approximately 0.05 to 0.2 billion cases of dengue infections are reported annually and the mortality rate due to dengue was above 20,000. The report has identified the rapid growth in disease incidences as one of the primary factors that will fuel the growth of the dengue vaccine market in the coming years. The prevalence of dengue is present in more than 125 countries across the world and the rising prevalence of dengue will drive the market during the forecast period.
The dengue vaccine market is marginally concentrated due to the presence and dominance of the established players. Several companies are investing in R&D to develop more advanced products and expand their product portfolio. Several organizations are merging for research and making enormous efforts to develop vaccines that can challenge the Sanofi Pasteur's exclusivity in the dengue treatment market. Moreover, several organizations are making huge investments in R&D to develop novel treatment options.
The Americas will be the major revenue contributor to the dengue vaccine market owing to the increasing incidences of dengue cases. The dengue treatment market in the Americas will profit from the bilateral program, Indo-U.S. Vaccine Action Program (VAP), which is concentrated on activities related to immunization and vaccine-related research.
The global Dengue Vaccine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dengue Vaccine market based on company, product type, end user and key regions.
This report studies the global market size of Dengue Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dengue Vaccine in these regions.
This research report categorizes the global Dengue Vaccine market by top players/brands, region, type and end user. This report also studies the global Dengue Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GlaxoSmithKline
Merck Sharp & Dohme
Sanofi
Takeda Pharmaceuticals
GeneOne Life Sciences
Medigen Biologics
Panacea Biotec
Sun Pharmaceutical
U.S NIH
Vabiotec
Market size by Product
CYD-TDV
DENVax or TAK-003
TetraVax-DV
TDENV PIV
V180
DNA vaccines
Market size by End User
Government institutions
Hospitals
NGOs
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Dengue Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Dengue Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Dengue Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Dengue Vaccine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Dengue Vaccine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dengue Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
With the increasing population density and global warming, there is a rapid growth in the prevalence of dengue, especially in the tropical and subtropical regions across the world. According to the National Institute of Health, approximately 0.05 to 0.2 billion cases of dengue infections are reported annually and the mortality rate due to dengue was above 20,000. The report has identified the rapid growth in disease incidences as one of the primary factors that will fuel the growth of the dengue vaccine market in the coming years. The prevalence of dengue is present in more than 125 countries across the world and the rising prevalence of dengue will drive the market during the forecast period.
The dengue vaccine market is marginally concentrated due to the presence and dominance of the established players. Several companies are investing in R&D to develop more advanced products and expand their product portfolio. Several organizations are merging for research and making enormous efforts to develop vaccines that can challenge the Sanofi Pasteur's exclusivity in the dengue treatment market. Moreover, several organizations are making huge investments in R&D to develop novel treatment options.
The Americas will be the major revenue contributor to the dengue vaccine market owing to the increasing incidences of dengue cases. The dengue treatment market in the Americas will profit from the bilateral program, Indo-U.S. Vaccine Action Program (VAP), which is concentrated on activities related to immunization and vaccine-related research.
The global Dengue Vaccine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dengue Vaccine market based on company, product type, end user and key regions.
This report studies the global market size of Dengue Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dengue Vaccine in these regions.
This research report categorizes the global Dengue Vaccine market by top players/brands, region, type and end user. This report also studies the global Dengue Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GlaxoSmithKline
Merck Sharp & Dohme
Sanofi
Takeda Pharmaceuticals
GeneOne Life Sciences
Medigen Biologics
Panacea Biotec
Sun Pharmaceutical
U.S NIH
Vabiotec
Market size by Product
CYD-TDV
DENVax or TAK-003
TetraVax-DV
TDENV PIV
V180
DNA vaccines
Market size by End User
Government institutions
Hospitals
NGOs
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Dengue Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Dengue Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Dengue Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Dengue Vaccine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Dengue Vaccine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dengue Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.